# OnCo record nct04092283 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04092283/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04092283", "NCT04092283" ;
  schema:name "Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Anti"@en ;
  schema:description "A phase 3 trial of carboplatin, cisplatin, durvalumab, etoposide and other drugs in lung cancer, run by National Cancer Institute (NCI), active but no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04092283/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04092283> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/stage-iii-unresectable-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pemetrexed/> .